Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Glauco-Viskin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actimed Therapeutics Showcases Clinical Pipeline Progress
    Actimed Therapeutics Showcases Clinical Pipeline Progress

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202077/0/en/Actimed-Therapeutics-to-Highlight-Advancing-Clinical-Pipeline-with-New-Data-Presentations-at-18th-Annual-Conference-on-Sarcopenia-Cachexia-and-Wasting-Disorders.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Mankind Pharma Signs Licensing Deal With Actimed For Cachexia
    Mankind Pharma Signs Licensing Deal With Actimed For Cachexia

    22 Nov 2025

    // PRESS RELEASE

    https://www.mankindpharma.com/media/press-release/actimed-therapeutics-announces-important-licensing-agreement-with-mankind-pharma/

    PRESS RELEASE
    22 Nov 2025
    Share Share
    Actimed Begins Ph2a Study of S-pindolol in Obese Patients
    Actimed Begins Ph2a Study of S-pindolol in Obese Patients

    25 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/25/3104816/0/en/Actimed-Therapeutics-Enrolls-First-Patients-in-Phase-2a-PROACT-Study-Programme-to-Assess-S-pindolol-benzoate-in-Obese-Patients-During-and-Post-GLP-1-Agonist-Therapy.html

    GLOBENEWSWIRE
    25 Jun 2025
    Share Share
    Actimed Publishes ACM-001.1 Phase 1 Data In Cachexia Journal
    Actimed Publishes ACM-001.1 Phase 1 Data In Cachexia Journal

    13 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/13/2996635/0/en/Actimed-Therapeutics-Announces-Publication-of-Successful-S-pindolol-benzoate-ACM-001-1-Phase-1-Study-in-The-Journal-of-Cachexia-Sarcopenia-and-Muscle.html

    GLOBENEWSWIRE
    13 Dec 2024
    Share Share
    Actimed gets US patent for ACM-001 & Canadian patent for ACM-002
    Actimed gets US patent for ACM-001 & Canadian patent for ACM-002

    14 Oct 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=143238&sid=2

    PHARMABIZ
    14 Oct 2021
    Share Share
    Bayshore Pharms` Generic Pindolol Receives Approval in US
    Bayshore Pharms` Generic Pindolol Receives Approval in US

    07 Aug 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211712

    FDA
    07 Aug 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.